Vistagen to acquire pherin pharmaceuticals

South san francisco, calif.--( business wire )--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, and pherin pharmaceuticals, inc., a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds for treatment of neuropsychiatric and neuroendocrine conditions (pherin), today announced that the companies have entered into a definitive agreement under which vistagen will acquire pherin for approximately 12.4 million shares of vistagen common stock and a nominal amount of cash.
VTGN Ratings Summary
VTGN Quant Ranking